Cargando…

Enrichment of mutations in chromatin regulators in people with Rett Syndrome lacking mutations in MECP2

PURPOSE: Rett Syndrome (RTT) is a neurodevelopmental disorder caused primarily by de novo mutations (DNMs) in MECP2 and sometimes in CDKL5 and FOXG1. However, some RTT cases lack mutations in these genes. METHODS: Twenty-two RTT cases without apparent MECP2, CDKL5, and FOXG1 mutations were subjected...

Descripción completa

Detalles Bibliográficos
Autores principales: Sajan, Samin A., Jhangiani, Shalini N., Muzny, Donna M., Gibbs, Richard A., Lupski, James R., Glaze, Daniel G., Kaufmann, Walter E., Skinner, Steven A., Anese, Fran, Friez, Michael J., Jane, Lane, Percy, Alan K., Neul, Jeffrey L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107176/
https://www.ncbi.nlm.nih.gov/pubmed/27171548
http://dx.doi.org/10.1038/gim.2016.42
_version_ 1782467169718632448
author Sajan, Samin A.
Jhangiani, Shalini N.
Muzny, Donna M.
Gibbs, Richard A.
Lupski, James R.
Glaze, Daniel G.
Kaufmann, Walter E.
Skinner, Steven A.
Anese, Fran
Friez, Michael J.
Jane, Lane
Percy, Alan K.
Neul, Jeffrey L.
author_facet Sajan, Samin A.
Jhangiani, Shalini N.
Muzny, Donna M.
Gibbs, Richard A.
Lupski, James R.
Glaze, Daniel G.
Kaufmann, Walter E.
Skinner, Steven A.
Anese, Fran
Friez, Michael J.
Jane, Lane
Percy, Alan K.
Neul, Jeffrey L.
author_sort Sajan, Samin A.
collection PubMed
description PURPOSE: Rett Syndrome (RTT) is a neurodevelopmental disorder caused primarily by de novo mutations (DNMs) in MECP2 and sometimes in CDKL5 and FOXG1. However, some RTT cases lack mutations in these genes. METHODS: Twenty-two RTT cases without apparent MECP2, CDKL5, and FOXG1 mutations were subjected to both whole exome sequencing and single nucleotide polymorphism array-based copy number variant (CNV) analyses. RESULTS: Three cases had MECP2 mutations initially missed by clinical testing. Of the remaining 19 cases, 17 (89.5%) had 29 other likely pathogenic intragenic mutations and/or CNVs (10 cases had two or more). Interestingly, 13 cases had mutations in a gene/region previously reported in other NDDs, thereby providing a potential diagnostic yield of 68.4%. These mutations were significantly enriched in chromatin regulators (corrected p = 0.0068) and moderately in postsynaptic cell membrane molecules (corrected p = 0.076) implicating glutamate receptor signaling. CONCLUSION: The genetic etiology of RTT without MECP2, CDKL5, and FOXG1 mutations is heterogeneous, overlaps with other NDDs, and complex due to high mutation burden. Dysregulation of chromatin structure and abnormal excitatory synaptic signaling may form two common pathological bases of RTT.
format Online
Article
Text
id pubmed-5107176
institution National Center for Biotechnology Information
language English
publishDate 2016
record_format MEDLINE/PubMed
spelling pubmed-51071762017-01-11 Enrichment of mutations in chromatin regulators in people with Rett Syndrome lacking mutations in MECP2 Sajan, Samin A. Jhangiani, Shalini N. Muzny, Donna M. Gibbs, Richard A. Lupski, James R. Glaze, Daniel G. Kaufmann, Walter E. Skinner, Steven A. Anese, Fran Friez, Michael J. Jane, Lane Percy, Alan K. Neul, Jeffrey L. Genet Med Article PURPOSE: Rett Syndrome (RTT) is a neurodevelopmental disorder caused primarily by de novo mutations (DNMs) in MECP2 and sometimes in CDKL5 and FOXG1. However, some RTT cases lack mutations in these genes. METHODS: Twenty-two RTT cases without apparent MECP2, CDKL5, and FOXG1 mutations were subjected to both whole exome sequencing and single nucleotide polymorphism array-based copy number variant (CNV) analyses. RESULTS: Three cases had MECP2 mutations initially missed by clinical testing. Of the remaining 19 cases, 17 (89.5%) had 29 other likely pathogenic intragenic mutations and/or CNVs (10 cases had two or more). Interestingly, 13 cases had mutations in a gene/region previously reported in other NDDs, thereby providing a potential diagnostic yield of 68.4%. These mutations were significantly enriched in chromatin regulators (corrected p = 0.0068) and moderately in postsynaptic cell membrane molecules (corrected p = 0.076) implicating glutamate receptor signaling. CONCLUSION: The genetic etiology of RTT without MECP2, CDKL5, and FOXG1 mutations is heterogeneous, overlaps with other NDDs, and complex due to high mutation burden. Dysregulation of chromatin structure and abnormal excitatory synaptic signaling may form two common pathological bases of RTT. 2016-05-12 2017-01 /pmc/articles/PMC5107176/ /pubmed/27171548 http://dx.doi.org/10.1038/gim.2016.42 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Sajan, Samin A.
Jhangiani, Shalini N.
Muzny, Donna M.
Gibbs, Richard A.
Lupski, James R.
Glaze, Daniel G.
Kaufmann, Walter E.
Skinner, Steven A.
Anese, Fran
Friez, Michael J.
Jane, Lane
Percy, Alan K.
Neul, Jeffrey L.
Enrichment of mutations in chromatin regulators in people with Rett Syndrome lacking mutations in MECP2
title Enrichment of mutations in chromatin regulators in people with Rett Syndrome lacking mutations in MECP2
title_full Enrichment of mutations in chromatin regulators in people with Rett Syndrome lacking mutations in MECP2
title_fullStr Enrichment of mutations in chromatin regulators in people with Rett Syndrome lacking mutations in MECP2
title_full_unstemmed Enrichment of mutations in chromatin regulators in people with Rett Syndrome lacking mutations in MECP2
title_short Enrichment of mutations in chromatin regulators in people with Rett Syndrome lacking mutations in MECP2
title_sort enrichment of mutations in chromatin regulators in people with rett syndrome lacking mutations in mecp2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107176/
https://www.ncbi.nlm.nih.gov/pubmed/27171548
http://dx.doi.org/10.1038/gim.2016.42
work_keys_str_mv AT sajansamina enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2
AT jhangianishalinin enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2
AT muznydonnam enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2
AT gibbsricharda enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2
AT lupskijamesr enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2
AT glazedanielg enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2
AT kaufmannwaltere enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2
AT skinnerstevena enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2
AT anesefran enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2
AT friezmichaelj enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2
AT janelane enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2
AT percyalank enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2
AT neuljeffreyl enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2